Skip to main content

ELB011 (Anti-CD160 antibody in ophthalmology)

ELB011 (Anti-CD160 antibody in ophthalmology)

Antibody to treat Age-related Macular Degeneration
Status: Candidate for the clinic selected

ELSALYS BIOTECH has developed a program based on the anti-angiogenic properties of the anti-CD160 antibody to treat vascular eye diseases and in particular Age-related Macular Degeneration (AMD).

Since this therapeutic domain is outside of the strategic field of activity of the company, ELSALYS BIOTECH has established a partnership with the THÉA Laboratories, a French pharmaceutical company specialized in ophthalmology, to develop this product under licence.

logo THEA

Mechanism of action of ELB011

ELSALYS BIOTECH has already performed preclinical studies with very promising results:

  • In rabbits, treatment with anti-CD160 blocks the formation of new blood vessels, similar to anti-VEGF agents, in a model of induced corneal angiogenesis
  • A combination treatment between an anti-CD160 and an anti-VEGF potentiates the anti-angiogenic effect, suggesting that the two biological pathways are at least partially independent
  • A first generation anti-CD160 limits the number of severe lesions induced with a laser and promotes their healing

Development plan and partnership with the THÉA Laboratories

On the basis of these results, ELSALYS BIOTECH has signed in January 2018 a licence option with the THÉA group for programme ELB011.

The next steps planned in the framework of this agreement are:

  • By the end of 2018: ELSALYS BIOTECH will continue the preclinical assays aiming for a proof of concept for the use of anti-CD160 antibodies in ophthalmology. The THÉA Laboratories will be able to exercise the option.
  • By the end of 2019: ELSALYS BIOTECH will perform, in name of THÉA Laboratories, the regulatory pre-clinical studies and will prepare the application to request an authorisation to perform a first clinical trial
  • By the end of 2020: the THÉA Laboratories will initiate the clinical development (as mono- and combination therapy).

Through this agreement, ELSALYS BIOTECH adds value to this first asset, demonstrates its ability to conclude partnerships with industry counterparts and, if successful, this partnership should become a complementary financial resource for the development of the Company.

Latest news on ELB011

Discover our latest news regarding our pipeline, our partnerships and more

Thu - 09, 11/08 - 09/2018 - 08:30

Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Thu, 02/22/2018 - 17:00
  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert


Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.